Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz242.024
Abstract: Abstract Background Palbociclib, the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). No real-world studies have examined relative effectiveness of palbociclib…
read more here.
Keywords:
real world;
palbociclib;
pfizer inc;
palbociclib plus ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1378
Abstract: Abstract Background COVID-19 disease severity has fluctuated with emergence of variants. To investigate disease severity in children, we analyzed clinical resource utilization among children hospitalized for COVID-19 during different variant periods in the United States.…
read more here.
Keywords:
delta omicron;
delta;
pre delta;
pfizer inc ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2203
Abstract: Abstract Background To assess the public health impact and economic value of an additional dose of BNT162b2 XBB.1.5-adapted COVID-19 vaccine 6 months after initial dose for those aged ≥65 years, compared to a single dose…
read more here.
Keywords:
pfizer inc;
public health;
additional dose;
pfizer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2218
Abstract: Abstract Background Immunocompromised individuals experience a disproportionate burden of COVID-19-associated hospitalization and death. COVID-19 vaccine uptake has declined over time. We evaluated XBB.1.5-adapted vaccine uptake, regardless of brand, during the 2023-2024 season among immunocompromised persons…
read more here.
Keywords:
pfizer inc;
xbb adapted;
vaccine uptake;
pfizer ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.1196
Abstract: Abstract Background A pneumococcal polysaccharide vaccine (PPSV23) has been available for use in adults ≥65 years old since 1983 with vaccination rates of ~65% in the past decade. A conjugate vaccine (PCV13) has been recommended…
read more here.
Keywords:
research;
adult;
pfizer inc;
serotype ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2434
Abstract: Background Patients (pts) with RA have increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors. Tofacitinib is an oral JAK inhibitor for the treatment of…
read more here.
Keywords:
pfizer inc;
risk;
mace;
mace risk ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1459
Abstract: Background Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral JAK inhibitor for the treatment of PsA. Objectives To investigate changes in…
read more here.
Keywords:
incidence;
pfizer;
pfizer inc;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1469
Abstract: Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes zoster (HZ) and this risk is further increased with tofacitinib…
read more here.
Keywords:
ada mtx;
pfizer inc;
pts received;
pfizer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3048
Abstract: Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signalling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk of venous thromboembolic events (VTE) in patients (pts) with rheumatoid…
read more here.
Keywords:
shareholder;
pfizer inc;
inc employee;
pfizer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3490
Abstract: Background Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function and homeostasis signal through JAKs, and reductions in mean lymphocyte count over time…
read more here.
Keywords:
pfizer;
pfizer inc;
bristol myers;
eli lilly ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1196
Abstract: Background Inflammatory arthritides affect joints variably despite systemic inflammatory cues. Anatomical site-specific differences have been seen in the transcriptome and function of synovial fibroblasts from different joints,1 including evidence that some joints in rheumatoid arthritis…
read more here.
Keywords:
pfizer;
pfizer inc;
treatment;
oral strategy ... See more keywords